Benzimidazole anthelmintic
Fenbendazole
Veterinary benzimidazole that binds parasite β-. Mammalian and metabolic effects are preclinical and are not established human indications.
Primary Mechanism of Action
Clinical / Scientific
Fenbendazole binds helminth β- similarly to other benzimidazoles, disrupting microtubules and parasite energy metabolism. Reports of mammalian disruption, p53-related signalling, or glucose- effects come from experimental models and must not be read as proven human therapy.
Pathway Targets
β-tubulin
Scientific explanation
disruption in susceptible helminths; mammalian effects are experimental.
Glucose transport
Scientific explanation
Preclinical reports of GLUT-related metabolic stress in cell models.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Parasite microtubule failure
Target to downstream effect: β-tubulin binding → Impaired trafficking and glucose handling → Parasite immobilization
Mechanistically Relevant Repurposed & Adjunctive Applications
Veterinary helminth infections
EstablishedMechanistic rationale
Established veterinary anthelmintic. Human labelled use is not implied by inclusion in this library.
Experimental antineoplastic microtubule stress
PreclinicalMechanistic rationale
Cell and animal studies have explored and metabolic stress. This is not an established cancer treatment.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| β-tubulin | Polymerization inhibition | Helminth cytoskeleton | Established mechanism (veterinary) |
| GLUT / glucose handling | Experimental metabolic stress | Oncology-related pathways in models | Preclinical |
In Plain Language
Fenbendazole is built like other worming benzimidazoles: it targets parasite microtubules. Laboratory ideas about human cancer biology remain experimental.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
β-tubulin
Oncology Mechanistic Relevance
Cancers in the atlas where this compound has a mapped mechanistic rationale. Evidence tiers are not equivalent and do not imply treatment.
Veterinary benzimidazole with preclinical and glucose-handling reports. Human oncology evidence is insufficient.
Veterinary benzimidazole with preclinical and glucose-handling reports. Human oncology evidence is insufficient.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.